Abheek Barua

It is now for the industry associations to agitate the matter before the government

In the grey markets, shares of Mankind Pharma enjoyed a premium of Rs 90, which translated to a likely listing price of Rs 1,170 per share on the upper price band

The RBI need not match the Fed one-to-one but there seems little scope to take its foot off the gas